NCT07167381Recruiting
xDRIVE for Florida-based Cancer Patients
xDRIVE Functional Precision Medicine + Artificial Intelligence Individualized Treatments for Florida-based Cancer Patients With Relapsed/ Refractory Cancers
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
Through this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision Medicine + Artificial Intelligence platform by assessing patient clinical benefit and health economics impacts. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment. The investigator will run a prospective single-arm feasibility study providing the xDRIVE FPM AI platform to n = 210+ cancer patients throughout the state of Florida, especially those from underserved populations (pediatric patients and patients in Black, Brown, Hispanic, and rural communities).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 210 (estimated)
- First submitted
- 24 Aug 2025
- Start date
- 1 Nov 2025
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- First Ascent Biomedical Inc.
- Diseases
- Childhood cancers
- NCT number
- NCT07167381
What you commit to
- Study type: Interventional
- Planned participants: 210
- From 1 Nov 2025 to the primary completion date, 1 Nov 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who do not have malignant tissue available and accessible, patients where the amount of excised malignant tissue is insufficient material for ex vivo drug testing and/or genetic profiling, defined as \<0.3g for resections or core/fine-needle biopsies not containing malignant tissue by pathology review, or insufficient malignant tissue in peripheral blood or bone marrow aspirate samples.
Other
- Patients with insufficient health indicators to undergo therapeutic intervention.
Who the study is looking for
- Patients with recurrent/refractory cancer patients up to age 18 (willing to sign assent if ages 7 - 17 years)
- -OR- Patients with recurrent/refractory cancer ≥18 years of age.
- Patients who have received at least one prior line of standard of care therapy.
- Patients able to provide treatment and outcome information from previous line(s) of therapy.
- Patients with sufficient health status to undergo cancer therapy, e.g., Eastern Cooperative Group (ECOG) performance status of 0, 1, or 2 for adult patients.
- Patients who are scheduled for or have recently undergone a tumor biopsy, excision, or resection.
- Patients willing to have a blood draw or buccal swab performed for matched normal material for comparison during tumor DNA profiling.
Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| First Ascent Biomedical Coordinator of this site? Confirm its status | Miami | United States | Recruiting |
| Florida International University Coordinator of this site? Confirm its status | Miami | United States | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.